BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization
Breast Cancer Research and Treatment · 2024
DOI: 10.1007/s10549-024-07271-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Rinat Yerushalmi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Davidoff Cancer Center, Rabin Medical Center, 39 Jabotinski St, 49414, Petah Tikva, Israel. rinaty@clalit.org.il. Hauptthemen laut MEDLINE: BRCA1 Protein, BRCA2 Protein, Mutation, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oncotest, Exact Sciences.
Abstract (Originalsprache)
Purpose
We compared 21-gene recurrence score (RS) distribution and expression of the single-gene/gene groups within this assay between BC patients with pathogenic variants (PV) in BRCA1/2 vs the general 21-gene-tested BC population.
Methods
This retrospective study included consecutive 21-gene-tested female ER + HER2-negative BC patients with germline PVs in BRCA1/2 . RS/gene expression data were compared to a previously described commercial use database (CDB, N = 799,986). Chi-square and 1-sample t test were used to compare RS distribution and single-gene/gene group scores between the study group and the CDB.
Results
Study group patients ( N = 81) were younger and their RS results were higher compared to the CDB (age: median [IQR], 56 [47–61.5] vs 60 [51–67] years; p < 0.001; proportion of patients with RS ≥ 26: 49.4% vs 16.4%, p < 0.001). Expression of 12/16 cancer genes in the assay and the ER, proliferation, and invasion gene group scores differed significantly between the study group and the CDB, all in a direction contributing to higher RS. The differences between the study group and the CDB were mostly retained, upon stratifying the patients by menopausal status.
Conclusion
BC patients with PVs in BRCA1/2 have higher RS results that stem from distinct gene expression profiles in the majority of genes in the 21-gene assay.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Davidoff Cancer Center, Rabin Medical Center, 39 Jabotinski St, 49414, Petah Tikva, Israel. rinaty@clalit.org.il.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. rinaty@clalit.org.il.
- Davidoff Cancer Center, Rabin Medical Center, 39 Jabotinski St, 49414, Petah Tikva, Israel.
- Radiation Oncology Dept, Sheba Medical Center, Ramat Gan, Israel.
- Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel.
- Faculty of Medicine, Hebrew University, Jerusalem, Israel.
Förderung
- Oncotest
- Exact Sciences
Zitieren
APA
Yerushalmi, R., Pomerantz, A., Lewin, R., Paluch-Shimon, S., Soussan-Gutman, L., Baehner, F. L., Voet, H., Bareket-Samish, A., Kedar, I., Goldberg, Y., Peretz-Yablonski, T., & Kadouri, L. (2024). BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07271-4
Vancouver
Yerushalmi R, Pomerantz A, Lewin R, Paluch-Shimon S, Soussan-Gutman L, Baehner FL, et al. BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07271-4
BibTeX
@article{Yerushalmi2024,
author = {Yerushalmi, Rinat and Pomerantz, Adi and Lewin, Ron and Paluch-Shimon, Shani and Soussan-Gutman, Lior and Baehner, Frederick L and Voet, Hillary and Bareket-Samish, Avital and Kedar, Inbal and Goldberg, Yael and Peretz-Yablonski, Tamar and Kadouri, Luna},
title = {BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization},
journal = {Breast Cancer Research and Treatment},
year = {2024},
doi = {10.1007/s10549-024-07271-4}
}
EUVIMED